Cue Biopharma, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 50.73 million compared to USD 53.01 million a year ago. Basic loss per share from continuing operations was USD 1.11 compared to USD 1.49 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 USD | +5.49% | -8.28% | -45.45% |
Apr. 08 | Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024 | |
Apr. 08 | North American Morning Briefing : Inflation Data, -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.45% | 66.4M | |
-2.78% | 103B | |
+1.39% | 95.28B | |
+1.46% | 22.15B | |
-15.80% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.08% | 16.05B | |
+5.13% | 13.68B | |
+33.65% | 12.17B |
- Stock Market
- Equities
- CUE Stock
- News Cue Biopharma, Inc.
- Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023